T1	Participants 59 121	previously untreated advanced esophagogastric cancer patients.
T2	Participants 382 507	patients within an open label, randomized clinical phase II trial with advanced or metastatic gastric/esophagogastric cancer.
T3	Participants 516 561	Previously untreated patients were randomized
T4	Participants 927 951	Of 118 patients enrolled
T5	Participants 1574 1629	levels in patients with advanced esophagogastric cancer
